JY
CLVS

Jeff Yass’s Clovis Oncology, Inc. CLVS Stock Holding History

Jeff Yass’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-505,343
Closed -$601K – 14378
2022
Q3 		$601K Sell
505,343
-655,945
-56% -$1.02M ﹤0.01% 7990
2022
Q2 		$2.09M Buy
1,161,288
+167,682
+17% +$247K ﹤0.01% 4825
2022
Q1 		$2.01M Sell
993,606
-362,275
-27% -$712K ﹤0.01% 5465
2021
Q4 		$3.67M Buy
1,355,881
+104,898
+8% +$388K ﹤0.01% 4286
2021
Q3 		$5.58M Buy
1,250,983
+323,597
+35% +$1.56M ﹤0.01% 3750
2021
Q2 		$5.38M Buy
927,386
+193,513
+26% +$1.13M ﹤0.01% 3907
2021
Q1 		$5.15M Buy
733,873
+44,778
+6% +$300K ﹤0.01% 3853
2020
Q4 		$3.31M Sell
689,095
-246,180
-26% -$1.25M ﹤0.01% 4144
2020
Q3 		$5.45M Sell
935,275
-253,087
-21% -$1.51M ﹤0.01% 2939
2020
Q2 		$8.02M Buy
1,188,362
+188,216
+19% +$1.43M ﹤0.01% 2397
2020
Q1 		$6.36M Buy
1,000,146
+966,111
+2,839% +$7.75M ﹤0.01% 2276
2019
Q4 		$355K Sell
34,035
-84,811
-71% -$617K ﹤0.01% 7669
2019
Q3 		$467K Sell
118,846
-427,766
-78% -$3.46M ﹤0.01% 7448
2019
Q2 		$8.13M Buy
546,612
+484,566
+781% +$8.76M ﹤0.01% 2112
2019
Q1 		$1.54M Sell
62,046
-603,466
-91% -$15.1M ﹤0.01% 4194
2018
Q4 		$12M Buy
665,512
+337,948
+103% +$6.91M ﹤0.01% 1447
2018
Q3 		$9.62M Buy
327,564
+197,807
+152% +$7.66M ﹤0.01% 1987
2018
Q2 		$5.9M Sell
129,757
-153,908
-54% -$7.49M ﹤0.01% 2512
2018
Q1 		$15M Sell
283,665
-82,508
-23% -$4.81M 0.01% 1450
2017
Q4 		$24.9M Buy
366,173
+250,808
+217% +$17.5M 0.01% 1101
2017
Q3 		$9.51M Buy
115,365
+63,008
+120% +$5M ﹤0.01% 1817
2017
Q2 		$4.9M Sell
52,357
-70,115
-57% -$4.29M ﹤0.01% 2438
2017
Q1 		$7.8M Buy
122,472
+18,794
+18% +$1.14M ﹤0.01% 1877
2016
Q4 		$4.61M Sell
103,678
-111,335
-52% -$3.92M ﹤0.01% 2555
2016
Q3 		$7.75M Buy
215,013
+152,492
+244% +$3.27M ﹤0.01% 1753
2016
Q2 		$858K Sell
62,521
-135,657
-68% -$1.98M ﹤0.01% 5167
2016
Q1 		$3.81M Sell
198,178
-171,389
-46% -$3.63M ﹤0.01% 2689
2015
Q4 		$12.9M Buy
369,567
+358,600
+3,270% +$23.1M 0.01% 1525
2015
Q3 		$1.01M Buy
10,967
+4,127
+60% +$357K ﹤0.01% 5738
2015
Q2 		$601K Buy
+6,840
New +$586K ﹤0.01% 7261
2015
Q1 		– Sell
-52,073
Closed -$3.68M – 10093
2014
Q4 		$2.92M Sell
52,073
-19,622
-27% -$1.03M ﹤0.01% 3796
2014
Q3 		$3.25M Sell
71,695
-51,829
-42% -$2.17M ﹤0.01% 3754
2014
Q2 		$5.12M Buy
123,524
+111,981
+970% +$5.77M ﹤0.01% 3038
2014
Q1 		$800K Sell
11,543
-39,959
-78% -$2.93M ﹤0.01% 5919
2013
Q4 		$3.1M Buy
51,502
+46,245
+880% +$2.52M ﹤0.01% 3613
2013
Q3 		$320K Sell
5,257
-5,644
-52% -$400K ﹤0.01% 7108
2013
Q2 		$730K Buy
+10,901
New +$490K ﹤0.01% 5490

Other funds holding CLVS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
CAS
Coppell Advisory Solutions Coppell, Texas $1.21B AUM 20.39% 1-Year Est. Return
CASC
Coppell Advisory Solutions Corp Coppell, Texas $531M AUM
STB
S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
FFWM
Future Financial Wealth Management Cincinnati, Ohio $160M AUM 21.24% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $808M AUM 51.1% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Jeff Yass's CLVS Position: Q4 2022 in Review

Jeff Yass sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 505,343 shares — an estimated $601K sold.

Jeff Yass first reported a position in CLVS in Q2 2013 and held it in 37 quarters. The position peaked at $24.9M in Q4 2017. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

  • Jeff Yass reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
  • Jeff Yass sold 505,343 Clovis Oncology, Inc. shares in Q4 2022, an estimated $601K.
  • Jeff Yass first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 37 quarters.
  • Jeff Yass's Clovis Oncology, Inc. position peaked at $24.9M in Q4 2017.
  • 15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Susquehanna International Group's 13F filing for Q4 2022, filed 14 Feb 2023.